

Drug and Therapeutics Committee – Minutes –Confirmed

Date / Time	Thursday 13 th June 2019 8:15am – 9:30am
Venue	Meeting Room 3, Womens & Childrens, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes

Attendance	Mr S P Gaines, Deputy Chief Pharmacist, Lead Pharmacist Medicine Safety Ms J Morgan, Professional Secretary, Senior Principal Pharmacist - Formulary Mr P O'Brien, Deputy Chief Pharmacist Dr S Raise, GP ER CCG (via phone link) Dr H Klonin, Consultant Paediatrician Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mr K McCorry, Medicines Optimisation Pharmacist, NECS (via phone link) Mr R Kapur, Vascular Surgeon Ms H Zhu, Visiting Pharmacist from China (guest)
Apologies	Dr F Umerah, Consultant Anaesthetist Dr O Ogunbambi, Consultant Rheumatologist Prof M Lind, Vice Chair, Professor of Oncology Dr A Samson, Infectious Diseases Consultant

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2019.06.01	Apologies	As above.					
2019.06.02	Declarations of Interest	None.					6/19
2019.06.03	Minutes of the previous meeting	Accepted as a true record.					6/19
2019.06.04	Action Tracker	<p>Minutes of Previous Meeting WH has amended minutes and changed CG103 to CG104</p> <p>Tracker: Erenumab KMc sent the section of minutes from Hull & ER CCG regarding Erenumab discussions</p> <p>Tracker – DOAC POB has written and circulated DOAC paper.</p> <p>NICE Guidance WH has updated formulary to include medical gases</p> <p>NICE Guidance TA567 Tisagenlecleucel ML not present to discuss if application has been requested.</p> <p>Chairs Approval OO has chased Benzbromarone application and it is on agenda for discussion</p> <p>NEW Product Requests ML has written to applicants and WH has updated formulary</p> <p>NICE Guidance WH informed the committee that the trust keeps licensed caffeine</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Discuss next time</p> <p>Action complete</p> <p>Action complete</p> <p>WH to update</p>	<p>WH</p> <p>KMc</p> <p>POB</p> <p>WH</p> <p>ML</p> <p>OO</p> <p>ML</p> <p>WH</p>	<p>6/19</p> <p>6/19</p> <p>6/19</p> <p>6/19</p> <p></p> <p>6/19</p> <p>6/19</p>		

		<p>citrate injection and unlicensed caffeine citrate solution. The committee agreed that the injection should be added to formulary and the solution should be added to the unlicensed list.</p> <p>NICE Guidance TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis. ML not present will inform if dermatology have been approached next time</p> <p>NICE Guidance TA575 Tildarkizumab for treating moderate to severe plaque psoriasis. ML not present will inform if dermatology have been approached next time</p> <p>NICE Guidance TA577 Brentuximab vedotin for treating CD30 positive cutaneous T cell lymphoma ML not present to update if HUTH willuse next time</p> <p>MHRA DSU SR has discussed yellow fever vaccine with practice nurses.</p> <p>Out of Hours Flowchart POB has discussed with on call pharmacists</p> <p>Correspondence Received WH has informed LC of chairs approval for Symtuza</p> <p>Correspondence Received WH has produced comparison table of Midazolam products and it is on agenda dor discussion.</p> <p>AOB POB has spoken to dermatology regarding sunsense products</p> <p>AOB WH has amended formulary to add sunsense and remove roc</p>	<p>formulary and unlicensed list</p> <p>Discuss next time</p> <p>Discuss next time</p> <p>Discuss next time</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>		<p>ML</p> <p>ML</p> <p>ML</p> <p>SR</p> <p>POB</p> <p>WH</p> <p>WH</p> <p>POB</p> <p>WH</p>		<p>6/19</p> <p>6/19</p> <p>6/19</p> <p>6/19</p> <p>6/19</p> <p>6/19</p>
2019.06.06	New Product Requests	<p>Benzbromarone – Gout – Dr O Ogunbambi Request is for unlicensed product to be used in patients who cannot tolerate allopurinol and febuxostat. Clinical evidence presented demonstrated that there is a greater risk of</p>	Approved	AM to write to applicants WH to update formulary	AM/WH	7/19	

		<p>developinghepatotoxicity in Japanese patients it was agreed that an information sheet would be prepared to cover this and that all patients would be monitored for liver function on a regular basis. As drug is unlicensed it would be red and provided by the trust</p> <p>Pristinamycin – Gram Positive Bacterial Infection – Dr C Eshiwe/L Cullen Requested with a view to use second line after Linezolid as a cheaper alternative to tedizolid. Would only be prescribed by infectious diseases and treated as an alert antibiotic.</p> <p>Oral Midazolam Ozalin® – Line Extension Requested as a line extension, but there are concerns as this is an oral preparation presented in a glass ampoule with a filter straw. Dose is determined in mg/KG but syringe is marked in Kg and relates to patients weight. There are serious safety concerns relating to the design of the product and the altered dosing regimen.</p> <p>Insulin Glargine Toujeo® Doublestar - Line extension 300units/ml – P Takkallapally Endocrinology Pharmacist HUTH currently stocks Toujeo solostar 300units/ml which uses one click per unit the request is for the doublestar device which used one click per two units, this is a concern for patients who remember their dose by the number of clicks required. There is also concern relating to dispensing errors due to similar packaging.</p>	Approved				
			Not approved -SG to take to Safe Medication	SG to feedback after SMPC	SG	7/19	
			Not approved - SG to take to Safe Medication	SG to feedback after SMPC	SG	7/19	
2019.06.06	NICE Guidance – April 2019	<p>NG127 Suspected neurological conditions: recognition and referral – no drugs mentioned</p> <p>NG128 Stroke and transient ischaemic attack in over 16s: diagnosis and initial management - All drugs on formulary</p> <p>NG 129 Crohn’s disease: management - All drugs on formulary</p> <p>NG130 Ulcerative colitis: management - All drugs on formulary</p>	Noted				6/19
			Noted				6/19
			Noted				6/19
			Noted				6/19

		<p>NG 131 Prostate cancer: diagnosis and management - All drugs on formulary</p> <p>NG132 Hyperparathyroidism (primary): diagnosis, assessment and initial management - All drugs on formulary</p> <p>TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation Not on formulary but WH informed committee that an ARIA form is being prepared</p> <p>TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy – no plans to use this combination as yet but oncology have said they will submit request if this changes</p> <p>TA580 Enzalutamide for hormone-relapsed non-metastatic prostate cancer NOT RECOMMENDED</p> <p>TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma</p> <p>TA582 Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)</p>	<p>Noted</p> <p>Noted</p> <p>Add to back of formulary until request received</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Noted</p>	<p>WH to add to formulary</p>	<p>WH</p>	<p>7/19</p>	<p>6/19</p> <p>6/19</p> <p>6/19</p> <p>6/19</p> <p>6/19</p> <p>6/19</p>
2019.06.07	MHRA Drug Safety Update – May 2019	<p>Lemtrada (Alemtuzumab) serious cardiovascular and immune mediated adverse reactions new restrictions to use and strengthened monitoring</p> <p>Tofacitinib (Xeljanz) – new restriction on 10mg BD daily dose in patients at high risk of pulmonary embolism while safety review is ongoing</p> <p>Magnesium Sulphate – Risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy - HK to speak to Jane Allen to find if out if HUTH use in this way</p>	<p>Noted</p> <p>AM to write to clinical leads for gastroenterology and rheumatology</p> <p>HK to speak to Jane Allen</p>		<p>AM</p> <p>HK</p>	<p>7/19</p> <p>7/19</p>	<p>6/19</p>

		Yellow Cards – please help to reduce the decline in reporting of suspected adverse drug reactions-there has been a national decrease in reporting however HUTH reporting has increased	No further action				6/19
2019.06.08	DOAC Briefing Paper	DC informed the committee that there had been an STP Medicines Optimisation meeting yesterday. There are many different ideas currently on how to implement and HUTH have agreed to hold back until an official proposal has been written	Noted – bring back when decision made	No further action			6/19
2019.06.09	Minutes from HERPC – March 2019	Noted	No further action				6/19
2019.06.10	Minutes from SMPC	None this month.					
2019.06.11	Regional Medicines Optimisation Committees	<ul style="list-style-type: none"> • Issue 3 Newsletter • Issue 4 Newsletter 	Noted				6/19
2019.06.12	Correspondence received	<p>Rivaroxaban letter from Bayer A new indication has been approved for the marketing authorisation of Xarelto 2.5mg:</p> <p>Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. The letter has been discussed by thrombosis committee who are not opposed to the new indication. RK informed the committee that HUTH had been involved in the trial</p>	WH to add to HERPC agenda		WH	7/19	
2019.06.13	Chairs approvals	<ul style="list-style-type: none"> • Benzbromarone – Gout – Dr E Middleton(Approved Apr 19) 	Noted	No further action			6/19
2019.06.14	Issues to escalate to OQC	No items to escalate					6/19

2019.06.15	Any Other Business	<p>JM informed the committee that Hull CCG have appointed a new prescribing lead Dr Bushra Ali, who should be invited to attend D&T</p> <p>Mexilitene Now available has a licensed product to treat Myotonia. HUTH currently have two patients receiving mexilitene one is a cardiac patient and the other is being treated under the pain clinic. POB proposed that HUTH continue to procure the imported unlicensed product.</p> <p>After meeting officially closed SG pointed out that Nitrofurantoin 100mg MR is not on HUTH formulary and this was recommended in current NICE guidance for the treatment of UTI, and is part of the CQUIN</p>	<p>AM to formally invite Dr Ali to attend</p> <p>Noted</p> <p>WH to arrange addition to formulary</p>		<p>AM</p> <p>WH</p>	<p>7/19</p> <p>7/19</p>	
2019.06.16	Date and Time of Next Meeting	<p>Date: Thursday 11th July 2019 Time: 8.15-9.30 Venue: Pathology Meeting Room</p>					